Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04774380
Title Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer (LUMINANCE)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca

lung small cell carcinoma


Cisplatin + Durvalumab + Etoposide

Carboplatin + Durvalumab + Etoposide

Age Groups: senior | adult
Covered Countries ITA | DEU | CAN

No variant requirements are available.